Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Background Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the pharmacologic profile and clinical outcomes for mavacamten and aficamten, 2 cardiac myos...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Bryton J. Davis, Hailey Volk, Olives Nguyen, Daniel Kamna, Hongya Chen, Roberto Barriales‐Villa, Pablo Garcia‐Pavia, Iacopo Olivotto, Anjali T. Owens, Caroline J. Coats, Theodore P. Abraham, Scott D. Solomon, Martin S. Maron, Ahmad Masri
Format:	Artigo
Język:	Inglês
Wydane:	Wiley 2025-03-01
Seria:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Hasła przedmiotowe:	aficamten cardiac myosin inhibitors mavacamten symptomatic hypertrophic cardiomyopathy
Dostęp online:	https://www.ahajournals.org/doi/10.1161/JAHA.124.038758
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!